In this report we explored the therapeutic potential of our platinum (IV) prodrugs in inducing anti-cancer activity to Cisplatin resistant and sensitive ovarian cancer cell lines and showed that the uptake of Cisplatin is partially dependent on Ctr1 transporter, while uptake of our platinum (IV) prodrugs is largely Ctr1-independent. The gene discussed is SLC31A1; the disease is ovarian carcinoma.